Pharmaceutical Costs

Utah State Legislator Introduces Bill to Import Prescription Drugs from Canada, Based on NASHP Model Legislation

Salt Lake City, Utah: Today, Republican state legislator Norman Thurston introduced groundbreaking legislation to create a safe, state-run prescription drug importation program that would import high-cost drugs from Canada, where prescription drugs cost 30 percent less than in the United States. The proposal for a whole-sale importation program of select, higher-cost drugs that are already […]

Read More
  • Reining in Rx Drug Costs: What States Achieved in 2017 and Where They’re Heading in 2018
    State Health Policy Blog

    In a year of tense partisan debate over the future of health care, one issue has achieved rare bipartisan agreement — the need to curb rising prescription drug costs. Polls show again and again that Americans, regardless of political affiliation, view the high costs of drugs as one of their chief health care concerns. Reviews […]

    Read More
  • The National Academy of Sciences recently released a report recommending several strategies to curb prescription drug costs that attempt to strike a balance between reining in prices while fostering continued drug development and innovation. Several of the academy’s recommendations are already getting trial runs in states, which are experimenting with innovative cost-savings approaches in order […]

    Read More
  • Is It Safe and Cost-Effective to Import Drugs from Canada?

    States are considering importing prescription drugs from Canada, but is it safe, will it save money, and can it be done? Three, easy-to-read infographics explain what state leaders need to know if they’re considering drug importation legislation. First, 40 percent of all drugs sold in the United States are already imported and 80 percent of […]

    Read More
  • Publications

    When states pass laws designed to control prescription drug costs, the pharmaceutical industry often responds with lawsuits claiming states are hindering interstate commerce and violating the federal Dormant Commerce Clause (DCC). NASHP’s legal experts believe states can craft drug cost policies that can withstand industry challenges. This brief by Anna Zaret and Darien Shankse provides insight and […]

    Read More
  • How States Can Avoid Dormant Commerce Clause Legal Challenges When Regulating Drug Costs
    State Health Policy Blog

    New state laws designed to control the costs of brand-name and generic prescription drugs often face legal challenges from the pharmaceutical industry. These lawsuits can vary depending on the individual state law, but recent industry lawsuits analyzed by the National Academy for State Health Policy (NASHP) share a common legal thread – drug manufacturers and […]

    Read More
  • Utah’s Norman Thurston Takes a Red State Approach to Lower Rx Costs with a Bill to Import Drugs from Canada
    State Health Policy Blog

    For more than a decade, Utah State Legislator and Director of the Office of Health Care Statistics Norman Thurston has worked to reform his state’s health care system, including its Medicaid program, and is considered one of the state’s “go-to” health care policymakers. Thurston, a Republican, has worked to reduce state spending on prescription drugs and […]

    Read More
  • At NASHP’s 30th State Health Policy Conference, state leaders from legislative and executive branches across the nation gathered to talk about what they are doing to manage escalating prescription drug costs in their states. Several states have recently passed or proposed legislation to force more transparency in drug pricing or to try to regulate drug […]

    Read More
  • NASHP Awards Grants to Colorado, Delaware, and Oklahoma to Tackle Rising Rx Drug Prices
    State Health Policy Blog

    The National Academy for State Health Policy (NASHP) has awarded $300,000 in grants to Colorado, Delaware, and Oklahoma to help the states develop innovative policy solutions to tackle high prescription drug prices. With the support from the Laura and John Arnold Foundation, the funding enables states to explore promising policy approaches to control rapidly escalating […]

    Read More
  • Lowering Drug Costs: Transparency Legislation Sets Off Flurry of New State Approaches
    State Health Policy Blog

    Responding to rapidly rising drug costs, 30 states across the country have drafted more than 60 drug price transparency bills designed to: Identify the costs that contribute to drug manufacturer expenses and list prices And unveil the often opaque business practices of pharmacy benefit managers (PBMs). In addition to promoting pricing transparency, as of early […]

    Read More